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Abstract 
Using a series of known inhibitors of the bacterial NorA efflux pump and the 
pharmacophore generation program CATALYST® the first predictive pharmacophore 
for inhibitors of this pump has been developed. The pharmacophore consists of 3 
hydrophobic features, a ring aromatic feature, 16 excluded volumes and one hydrogen 
bond acceptor. This pharmacophore was subsequently used to search the NCI database 
for new compound leads and also for de novo design. Two 1,4-naphthoquinones and an 
aromatic azo compound were identified as possible leads from the NCI database of 
compounds. These compounds were tested for NorA efflux inhibition in Staphylococcus 
aureus and they showed inhibitory activity. The de novo design process identified a 
number of new biaryl ether and biaryl ketone target compounds as potential inhibitors. 
A biaryl ether target 2-[3-(3-methoxyphenoxy)phenyl]isoindoline-1,3-dione, was 
synthesised by a concise three step process. This compound showed moderate NorA 
pump inhibitory activity in Staphylococcus aureus, using berberine as the antibacterial 
pump substrate. Thus this biaryl ether could serve as the starting point for a new class of 
inhibitors. 
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